MedTrace Logo

Use of Thalidomide in Chronic Uveitis

NCT00314665 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2007-12-06

No results posted yet for this study

Summary

This research study is for patients that have been diagnosed with chronic uveitis, a disease that causes inflammation in the eye. Patients are currently being treated with Remicade, Humira, Methotrexate and or similar chemotherapy type drugs to control this inflammation. Despite these medications, patients still have inflammation in their eyes. Patients are being asked to add an additional drug, thalidomide.

Conditions

  • Uveitis

Interventions

DRUG

Thalidomide

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · Professor of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314665 on ClinicalTrials.gov